On The Horizon: New Oral Therapies for Type 2 Diabetes Mellitus
Journal Title: International Journal of Diabetology & Vascular Disease Research (IJDVR) - Year 2013, Vol 1, Issue 3
Abstract
The first documented case of diabetes mellitus occurred earlier than 4000 BC. Since then, many of the brightest minds in medicine have dedicated their time and effort toward developing treatments that can reverse the course of this deadly disease. As our understanding of the pathogenesis of diabetes increases, so does the availability of treatment options. The fight against diabetes once only had metformin and sulfonylureas as the cornerstone of oral treatment, but now, multiple classes have been added to this armamentarium including thiazolidenediones (TZDs) and dipeptidyl peptidase IV (DDP IV) inhibitors. These therapies provide reasonable durable glycemic control but are unable to arrest the natural progression of diabetes or the eventual need for insulin. By utilizing our growing knowledge on the pathogenesis of diabetes, a number of new therapeutic agents are in development to overcome the shortcomings of current therapies. Promising options on the horizon include sodium-coupled glucose cotransport 2 (SGLT2) inhibitors, Ranolazine, Salicylates, second generation Peroxisome proliferator ac-tivator receptor agonists (PPARs), and 11-beta hydroxysteroid dehydrogenase type 1 inhibitors (11-beta HSD1 inhibitors). Various molecules, including some enzymes, are also in development particularly to address beta cell preservation and its sensitivity to glucose, while minimizing hypoglycemia. Most of these new classes of drugs consist of daily administration, simplifying the regimen for patients and likely increasing medication compliance. This article reviews the new agents that are advancing through clinical trials, their mechanism of actions, glucose lowering effect and possible side effects and limitations
Authors and Affiliations
Intekhab Ahmed
Keywords
Related Articles
- EP ID EP197782
- DOI 10.19070/2328-353X-130004
- Views 158
- Downloads 0
Total Adiponectin and Risk of Symptomatic Lower Extremity Peripheral Vascular Disease in Type 2 Diabetes Mellitus
Objective: Adiponectin is an adipocyte-derived protein that has gained considerable research interest because of its pleiotropic effects on insulin sensitivity, atherosclerosis and inflammation. Lower concentrations of a...
Glycated Albumin: A More Sensitive Predictor of Cardiovascular Disease than Glycated Hemoglobin?
Glycated Albumin: A More Sensitive Predictor of Cardiovascular Disease than Glycated Hemoglobin?
Treatment of Hypercholesterolemia in Patients with Diabetes Mellitus
Numerous studies have shown that statins reduce cardiovascular events including stroke and mortality in diabetics. The American Diabetes. Association 2013 guidelines recommend that diabetics at high risk for cardiovascul...
Nature as an Ideal Rhythm Model for Optimal Cardiovascular Physiology and Health
This article innovatively describes nature as an ultimate rhythm model for optimizing human physiology and health. Circadian rhythms of biological systems orchestrate cell metabolism and survivorship for reasonable longe...
Prevalence of Major Risk Factors for Cardiovascular Disease in Patients With Diabetes. Data from The Ukrainian Endovascular Register
The analysis of the incidence of a number of risk factors for coronary heart disease in 2,700 people with angio-graphically documented coronary atherosclerosis in the electronic register of the Department of Intervention...